Dalotuzumab
Dalotuzumab is a humanized monoclonal antibody designed for the treatment of cancers.[1]
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Humanized (from mouse) |
Target | IGF-1 receptor |
Clinical data | |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
KEGG | |
ECHA InfoCard | 100.205.569 |
Chemical and physical data | |
Formula | C6528H10086N1730O2018S40 |
Molar mass | 146374.99 g·mol−1 |
NY (what is this?) (verify) |
Dalotuzumab was developed by Merck & Co., Inc.
References
Angiopoietin |
| ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
CNTF | |||||||||||
EGF (ErbB) |
| ||||||||||
FGF |
| ||||||||||
HGF (c-Met) |
| ||||||||||
IGF |
| ||||||||||
LNGF (p75NTR) |
| ||||||||||
PDGF |
| ||||||||||
RET (GFL) |
| ||||||||||
SCF (c-Kit) | |||||||||||
TGFβ |
| ||||||||||
Trk |
| ||||||||||
VEGF |
| ||||||||||
Others |
| ||||||||||
|
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.